RabGGTase inhibitors (Lead Discovery)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRabGGTase inhibitors (Lead Discovery)
Drug Alias NameRab geranylgeranyltransferase inhibitors (Lead Discovery)LDC-2978
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein farnesyltransferase inhibitors
TargetsProtein farnesyltransferase
Therapy Area/IndicationsThrombosisEpilepsyNeoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLead Discovery Center GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLead Discovery Center GmbH
Active IndicationsN/A
Inactive IndicationsThrombosisEpilepsyNeoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A